Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News TNF Pharmaceuticals Inc TNFA

Healthcare
TNF Pharmaceuticals, Inc., formerly MyMD Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on developing novel therapies for age-related diseases and autoimmune and inflammatory conditions. It is focused on developing and commercializing two therapeutic platforms based on well-defined therapeutic targets: MYMD-1 and Supera-CBD. MYMD-1 is a drug platform based on a... see more

Recent & Breaking News (NDAQ:TNFA)

MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022

Business Wire December 6, 2022

MyMD Pharmaceuticals® Announces Upcoming Presentation of Late-Breaking Data for MYMD-1® at the 2022 British Society for Immunology (BSI) Congress

Business Wire November 17, 2022

MyMD Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1® in Peer-Reviewed Journal Drug Research

Business Wire November 14, 2022

MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan

Business Wire September 20, 2022

MyMD Pharmaceuticals Receives Grant From European Patent Office for Supera-CBD(TM) Compound

Business Wire August 30, 2022

Data Showing MyMD Pharmaceuticals' MYMD-1® May Extend Life and Improve Health Published in the Journal of Gerontology: Biological Sciences

Business Wire August 3, 2022

MyMD Pharmaceuticals® Advances Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan

Business Wire July 26, 2022

MyMD Pharmaceuticals to Collaborate with Bascom Palmer Eye Institute to Study MYMD-1 in Ophthalmic Conditions

Business Wire July 12, 2022

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating MyMD Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

PR Newswire July 7, 2022

MyMD Pharmaceuticals Advances Phase 2 Multi-Center Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan

Business Wire June 21, 2022

MyMD Pharmaceuticals Accelerates Pace of New Patient Dosing in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan

Business Wire April 5, 2022

MyMD Pharmaceuticals Announces Live Appearance on Cheddar News Network Today March 24

Business Wire March 24, 2022

MyMD Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan

Business Wire February 23, 2022

MyMD Pharmaceuticals Announces Positive Clinical Data in Advance of Upcoming Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan

Business Wire February 8, 2022

MyMD Pharmaceuticals Announces Issuance of New U.S. Patent Covering MYMD-1 in a Method of Treating Sarcopenia

Business Wire January 5, 2022

MyMD Pharmaceuticals Investment Company Oravax Medical Signs Cooperation and Purchase Agreement for Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccine to be Commercialized in Southeast Asia

Business Wire December 29, 2021

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating MyMD Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

PR Newswire December 16, 2021

MyMD Pharmaceuticals to Participate in Two Investor Conferences During December 2021

Business Wire December 1, 2021

MyMD Pharmaceuticals Announces Issuance of U.S. Patent Covering Lead Drug Candidate MYMD-1 in a Method of Extending Lifespan

Business Wire November 23, 2021

MyMD Pharmaceuticals Investment Company Oravax Medical and Genomma Lab Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin America

Business Wire November 18, 2021